Under construction – not a live service
Sign in
Taking people in GreeceNo phase

Studies follow-up treatments after bone-building drugs in postmenopausal women with osteoporosis

Observes which medicines follow bone-building injections in women with severe bone thinning.

Plain-language title generated from the registry record
Registry title: Sequential Therapies After Osteoanabolic Treatment

Key facts

Where
Athens and Thessaloniki, GreeceSee the 4 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for postmenopausal women with severe osteoporosis who have finished a course of romosozumab or teriparatide. It follows what happens with the next treatments for 12 months.

Age
50 to 85 years
Sex
Women only
Disease stage
Severe osteoporosis after menopause
Earlier treatment
Must have completed a course of romosozumab or teriparatide. Must not have used other medicines that affect bone in the last 12 months.
Biomarker or test result
Blood vitamin D (25-OHD) must not be lower than 20 ng/mL (50 nmol/L).

Main reasons for not taking part

  • A bone disease other than postmenopausal osteoporosis
  • Creatinine clearance below 60 mL/min/1.73 m2
  • Liver failure
  • Any type of cancer
  • Uncontrolled endocrine diseases

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 85 years old?

Source: NCT06164795, who can take part

Where in Greece

  • 251 Airforce & VA General HospitalAthens, GreeceContact: Polyzois Makras, PhDTaking people
  • First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of AthensAthens, GreeceContact: Maria P Yavropoulou, ConsultantTaking people
  • KAT General HospitalAthens, GreeceContact: Symeon Tournis, PhDTaking people
  • 424 General Military HospitalThessaloniki, GreeceContact: Athanasios D Anastasilakis, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
424 General Military Hospital
Trial code
NCT06164795
Record updated
22 July 2026
Original description
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolicsRead full original descriptionShow less

Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) Study

12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics

Inclusion: Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide.

Exclusion: use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study; a bone disease other than postmenopausal osteoporosis; liver failure; any type of cancer; uncontrolled endocrine diseases; hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients; creatinine clearance <60 mL/min/1.73 m2; serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L).

ClinicalTrials.gov NCT06164795